Metformin and ovarian cancer survival: is there a rational warrant for belief?
Metformin (MF) represents the first-line drug used to treat type 2 diabetes. Recently, MF has also been reported to be a potential and promising anti-cancer agent for some gynecological cancers' prevention. MF, as an anti-tumorigenic factor, may reduce the chance of developing ovarian cancer by targeting IL-6. By acting on IL-6 expression, metformin might have a positive impact on the main molecular pathways strictly connected with pathogenesis and biological features of ovarian cancer. Further investigation is warranted to better define the use of MF as a possible treatment option in the fight against ovarian cancer.